ProMIS Neurosciences Inc. Common Shares (ON)PMN
Scheduled
ProMIS Neurosciences Inc. Common Shares (ON) Moody Capital Disruptive Growth & Life Science Conference
Review the key takeaways and the transcript of this earnings call.
Period 0
Key takeaways
- ProMIS Neurosciences is a clinical-stage biotech company developing therapeutic antibodies targeting neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's disease.
- The company is publicly traded on NASDAQ under the ticker PMN and recently raised up to $175 million in February from top long-term institutional investors.
- ProMIS's technology focuses on protein misfolding and designs monoclonal antibodies that specifically target misfolded epitopes unique to toxic oligomers implicated in diseases like Alzheimer's.
- Their lead Alzheimer's candidate, PMN-310, targets toxic beta amyloid oligomers while avoiding plaques and monomers, differentiating it from existing drugs like lecanemab and donanemab which bind all amyloid beta forms and are associated with serious side effects such as ARIA (swelling and bleeding in the brain).
- The ongoing Phase 1B clinical trial enrolled 144 early Alzheimer's patients with mild cognitive impairment, using a randomized 3:1 active to placebo design with monthly dosing over 12 months.
- An interim blinded analysis at six months showed PMN-310 to be very safe with zero cases of ARIA-E (edema) and ARIA-H (hemorrhage) rates comparable to placebo background levels, significantly better than the 12-24% ARIA rates seen with marketed drugs.
- Biomarker data from the interim analysis showed a 15% reduction in PTAU217, a key Alzheimer's disease progression marker, and similar downward trends in MTBR TAU243, indicating potential target engagement and early efficacy signals.
- Enrollment completed last year, and the company has received FDA Fast Track designation for PMN-310.
- Final topline unblinded data from the Phase 1B trial is expected in Q1 2027, with plans to discuss clinical efficacy at that time.
- ProMIS is developing a subcutaneous formulation of PMN-310 and preparing for a potential Phase 3 registration study based on the Phase 1B results and FDA feedback.
- The company also has preclinical candidates targeting misfolded TDP-43 for ALS and misfolded alpha-synuclein for Parkinson's disease.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring